What Is Arcus Biosciences, Inc. (RCUS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Arcus Biosciences, Inc.'s intrinsic value is estimated at $8.69, suggesting the stock is overvalued at its current price of $28.33. With 11 out of 12 models flagging downside (-69.3% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $30.93 (+9.2%), versus ML-RIV at $0.21 (-99.3%). This +108.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About RCUS?
12 of 13 models are currently active for RCUS. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates RCUS's intrinsic value at $6.67, implying -76.5% downside from the current price. See which stocks rank higher →
How Does RCUS Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, RCUS ranks #77 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Arcus Biosciences, Inc. operates in a sector where R&D productivity ratio is a critical driver of valuation. Investors evaluating RCUS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is RCUS a Value Trap?
CirclFi's Value Trap algorithm assigns RCUS a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Arcus Biosciences, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Arcus Biosciences, Inc.'s fundamental quality profile registers 6.8/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +108.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RCUS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RCUS's 12 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad